Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

May 12, 2017: By Joan McKenna

SightLifeSurgicalPaul Bernard “Bernie” Haffey has joined SightLife Surgical as its first chief commercial officer.

SightLife Surgical, founded in 2016, is a Seattle-based for-profit subsidiary of SightLife that provides comprehensive services to support ophthalmic surgeons, from corneal tissue and devices to reimbursement consulting and political advocacy.

“Given our ambitions to accelerate discoveries that will benefit the cornea world, from surgeons to patients, Bernie’s background launching emerging medical technology companies, as well as his proven history of creating shareholder value, will help us reach our goal to eliminate corneal blindness by 2040,” said Monty Montoya, SightLife Surgical president and CEO.

Most recently, Haffey served as president and CEO of Nexis Vision, Inc., and president and CEO of NDO Surgical, Inc. He also served as executive vice president and chief commercial officer at Summit Technology, Inc., and as executive vice president and chief commercial officer at IntraLase Corp. In addition to his role at SightLife, Bernie serves as president of 2020 Management Consulting, Inc.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023